[{"id":"33062010-2f9f-457a-bb48-293b21b77b51","acronym":"RAGNAR","url":"https://clinicaltrials.gov/study/NCT04083976","created_at":"2021-01-18T19:59:45.508Z","updated_at":"2025-02-25T12:37:25.290Z","phase":"Phase 2","brief_title":"A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations","source_id_and_acronym":"NCT04083976 - RAGNAR","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" FGFR2 • FGFR • TACC3 • TACC2","pipe":" | ","alterations":" FGFR3 mutation • FGFR mutation • FGFR fusion","tags":["FGFR2 • FGFR • TACC3 • TACC2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR3 mutation • FGFR mutation • FGFR fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Balversa (erdafitinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 316","initiation":"Initiation: 11/20/2019","start_date":" 11/20/2019","primary_txt":" Primary completion: 12/04/2023","primary_completion_date":" 12/04/2023","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-24"},{"id":"9c7ac936-fde1-4b07-9296-dad7240ad183","acronym":"","url":"https://clinicaltrials.gov/study/NCT04963153","created_at":"2021-07-15T13:06:11.818Z","updated_at":"2025-02-25T12:28:14.832Z","phase":"Phase 1","brief_title":"Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy","source_id_and_acronym":"NCT04963153","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • FGFR2 • NECTIN4","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • FGFR2 • NECTIN4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Balversa (erdafitinib) • Padcev (enfortumab vedotin-ejfv)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/07/2022","start_date":" 07/07/2022","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-02-24"},{"id":"360b90be-2213-4d23-b6e5-cc0f96b7a6e3","acronym":"","url":"https://clinicaltrials.gov/study/NCT04238715","created_at":"2021-01-19T19:12:02.961Z","updated_at":"2025-02-25T14:40:28.907Z","phase":"Phase 2","brief_title":"A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion","source_id_and_acronym":"NCT04238715","lead_sponsor":"Eisai Co., Ltd.","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 fusion","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tasfygo (tasurgratinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 01/22/2020","start_date":" 01/22/2020","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2025-02-14"},{"id":"3a138d15-6bca-4eff-8361-765e025c0dc8","acronym":"FORTITUDE-101","url":"https://clinicaltrials.gov/study/NCT05052801","created_at":"2021-09-22T11:53:35.151Z","updated_at":"2025-02-25T16:38:37.071Z","phase":"Phase 3","brief_title":"Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression","source_id_and_acronym":"NCT05052801 - FORTITUDE-101","lead_sponsor":"Amgen","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 overexpression • FGFR2b overexpression","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 overexpression • FGFR2b overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • leucovorin calcium • bemarituzumab (AMG 552)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 547","initiation":"Initiation: 03/07/2022","start_date":" 03/07/2022","primary_txt":" Primary completion: 08/18/2025","primary_completion_date":" 08/18/2025","study_txt":" Completion: 08/18/2025","study_completion_date":" 08/18/2025","last_update_posted":"2025-02-07"},{"id":"b9a406bd-d975-4b31-a433-86da8522fc92","acronym":"TAS-120-202","url":"https://clinicaltrials.gov/study/NCT04189445","created_at":"2021-01-19T19:00:59.221Z","updated_at":"2025-02-25T16:44:46.191Z","phase":"Phase 2","brief_title":"Futibatinib in Patients With Specific FGFR Aberrations","source_id_and_acronym":"NCT04189445 - TAS-120-202","lead_sponsor":"Taiho Oncology, Inc.","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 amplification • FGFR1 rearrangement","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 amplification • FGFR1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lytgobi (futibatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 115","initiation":"Initiation: 08/24/2020","start_date":" 08/24/2020","primary_txt":" Primary completion: 11/11/2024","primary_completion_date":" 11/11/2024","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2025-02-05"},{"id":"79a21cb0-b80b-4f09-9b9e-bdba02cd1248","acronym":"IMPACT","url":"https://clinicaltrials.gov/study/NCT01505400","created_at":"2021-01-18T06:19:22.670Z","updated_at":"2025-02-25T16:58:29.958Z","phase":"","brief_title":"Integrated Molecular Profiling in Advanced Cancers Trial","source_id_and_acronym":"NCT01505400 - IMPACT","lead_sponsor":"University Health Network, Toronto","biomarkers":" EGFR • HER-2 • PIK3CA • FGFR2 • STK11 • HRAS • PDGFRA • JAK2 • AKT1 • FGFR4 • CTNNB1","pipe":"","alterations":" ","tags":["EGFR • HER-2 • PIK3CA • FGFR2 • STK11 • HRAS • PDGFRA • JAK2 • AKT1 • FGFR4 • CTNNB1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 3026","initiation":"Initiation: 02/01/2012","start_date":" 02/01/2012","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-03"},{"id":"9d94409b-3124-4594-8d29-7cfddaf92a43","acronym":"FOENIX-CCA4","url":"https://clinicaltrials.gov/study/NCT05727176","created_at":"2023-02-14T18:02:28.005Z","updated_at":"2025-02-25T17:02:23.376Z","phase":"Phase 2","brief_title":"Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement","source_id_and_acronym":"NCT05727176 - FOENIX-CCA4","lead_sponsor":"Taiho Oncology, Inc.","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 fusion • FGFR2 rearrangement","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 fusion • FGFR2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lytgobi (futibatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 07/05/2023","start_date":" 07/05/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-03"},{"id":"ef460ada-1956-4c98-ae47-6b4d433dca90","acronym":"ReFocus","url":"https://clinicaltrials.gov/study/NCT04526106","created_at":"2021-01-18T21:40:34.651Z","updated_at":"2025-02-25T17:30:23.437Z","phase":"Phase 1/2","brief_title":"REFOCUS: a First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with ICC and Other Advanced Solid Tumors","source_id_and_acronym":"NCT04526106 - ReFocus","lead_sponsor":"Elevar Therapeutics","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 mutation • FGFR2 fusion","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation • FGFR2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lirafugratinib (RLY-4008)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 490","initiation":"Initiation: 09/02/2020","start_date":" 09/02/2020","primary_txt":" Primary completion: 09/27/2024","primary_completion_date":" 09/27/2024","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-01-30"},{"id":"5c88c63c-d256-4f58-81e6-5b70704df6d0","acronym":"","url":"https://clinicaltrials.gov/study/NCT06632262","created_at":"2025-02-26T15:04:35.295Z","updated_at":"2025-02-26T15:04:35.295Z","phase":"Phase 2","brief_title":"A Phase 2 Clinical Study of ABSK061 and ABSK043","source_id_and_acronym":"NCT06632262","lead_sponsor":"Abbisko Therapeutics Co, Ltd","biomarkers":" HER-2 • FGFR2 • FGFR3","pipe":"","alterations":" ","tags":["HER-2 • FGFR2 • FGFR3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABSK043 • lavengratinib (ABSK061)"],"overall_status":"Recruiting","enrollment":" Enrollment 202","initiation":"Initiation: 11/13/2024","start_date":" 11/13/2024","primary_txt":" Primary completion: 11/30/2029","primary_completion_date":" 11/30/2029","study_txt":" Completion: 06/30/2030","study_completion_date":" 06/30/2030","last_update_posted":"2024-11-19"},{"id":"678c2f57-c2a1-4d53-9b3f-1c28268db167","acronym":"","url":"https://clinicaltrials.gov/study/NCT05174650","created_at":"2022-01-03T15:00:36.712Z","updated_at":"2025-02-25T13:36:03.205Z","phase":"Phase 2","brief_title":"Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements","source_id_and_acronym":"NCT05174650","lead_sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 fusion","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • derazantinib (ARQ 087)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 04/20/2022","start_date":" 04/20/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-07-24"},{"id":"e9547fb4-4cd2-4f5f-b4e3-ae7528896751","acronym":"FIRST-308","url":"https://clinicaltrials.gov/study/NCT05948475","created_at":"2023-07-17T14:08:53.898Z","updated_at":"2024-07-02T16:34:27.046Z","phase":"Phase 3","brief_title":"Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma","source_id_and_acronym":"NCT05948475 - FIRST-308","lead_sponsor":"TransThera Sciences (Nanjing), Inc.","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 fusion","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • irinotecan • tinengotinib (TT-00420)"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 12/20/2023","start_date":" 12/20/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-06-12"},{"id":"e79a541e-0cd8-480b-90cf-f790043b9fc7","acronym":"FORTITUDE-102","url":"https://clinicaltrials.gov/study/NCT05111626","created_at":"2021-11-08T14:53:12.581Z","updated_at":"2024-07-02T16:34:59.979Z","phase":"Phase 3","brief_title":"Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer","source_id_and_acronym":"NCT05111626 - FORTITUDE-102","lead_sponsor":"Amgen","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 overexpression • FGFR2b overexpression","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 overexpression • FGFR2b overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • bemarituzumab (AMG 552)"],"overall_status":"Recruiting","enrollment":" Enrollment 528","initiation":"Initiation: 03/14/2022","start_date":" 03/14/2022","primary_txt":" Primary completion: 09/26/2026","primary_completion_date":" 09/26/2026","study_txt":" Completion: 09/26/2026","study_completion_date":" 09/26/2026","last_update_posted":"2024-05-30"},{"id":"eb57432c-2617-48dd-9e9e-25c0afd719ac","acronym":"CIBI375A201","url":"https://clinicaltrials.gov/study/NCT04256980","created_at":"2021-01-19T19:16:58.237Z","updated_at":"2024-07-02T16:35:00.136Z","phase":"Phase 2","brief_title":"Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement","source_id_and_acronym":"NCT04256980 - CIBI375A201","lead_sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 rearrangement","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pemazyre (pemigatinib)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 03/03/2020","start_date":" 03/03/2020","primary_txt":" Primary completion: 01/29/2021","primary_completion_date":" 01/29/2021","study_txt":" Completion: 08/31/2023","study_completion_date":" 08/31/2023","last_update_posted":"2024-05-30"},{"id":"c8879055-5cfc-4980-bb0d-ebf82077c424","acronym":"FOENIX-MBC2 TAS-120-201","url":"https://clinicaltrials.gov/study/NCT04024436","created_at":"2021-01-18T19:45:26.836Z","updated_at":"2024-07-02T16:35:00.592Z","phase":"Phase 2","brief_title":"A Study of TAS-120 in Patients With Metastatic Breast Cancer","source_id_and_acronym":"NCT04024436 - FOENIX-MBC2 TAS-120-201","lead_sponsor":"Taiho Oncology, Inc.","biomarkers":" HER-2 • PD-L1 • FGFR2","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative • FGFR1 amplification • FGFR2 amplification","tags":["HER-2 • PD-L1 • FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative • FGFR1 amplification • FGFR2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • Lytgobi (futibatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 168","initiation":"Initiation: 08/30/2019","start_date":" 08/30/2019","primary_txt":" Primary completion: 05/31/2023","primary_completion_date":" 05/31/2023","study_txt":" Completion: 07/05/2024","study_completion_date":" 07/05/2024","last_update_posted":"2024-05-29"},{"id":"23311617-41c6-44fc-9230-357b9b804a7b","acronym":"FIGHT-302","url":"https://clinicaltrials.gov/study/NCT03656536","created_at":"2021-01-19T16:33:21.014Z","updated_at":"2024-07-02T16:35:02.376Z","phase":"Phase 3","brief_title":"A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma","source_id_and_acronym":"NCT03656536 - FIGHT-302","lead_sponsor":"Incyte Corporation","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 rearrangement","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • Pemazyre (pemigatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 434","initiation":"Initiation: 06/03/2019","start_date":" 06/03/2019","primary_txt":" Primary completion: 10/26/2027","primary_completion_date":" 10/26/2027","study_txt":" Completion: 07/27/2028","study_completion_date":" 07/27/2028","last_update_posted":"2024-05-21"},{"id":"f1eb15be-99b0-4993-89d8-1f3e74e59506","acronym":"","url":"https://clinicaltrials.gov/study/NCT05297903","created_at":"2022-03-28T13:52:59.235Z","updated_at":"2024-07-02T16:35:05.357Z","phase":"Phase 2","brief_title":"XmAb20717 in Advanced Biliary Tract Cancers","source_id_and_acronym":"NCT05297903","lead_sponsor":"Abramson Cancer Center at Penn Medicine","biomarkers":" FGFR2 • IDH1 • NTRK","pipe":" | ","alterations":" IDH1 mutation • FGFR2 mutation • FGFR2 fusion • NTRK fusion","tags":["FGFR2 • IDH1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • FGFR2 mutation • FGFR2 fusion • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vudalimab (XmAb717)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 04/11/2022","start_date":" 04/11/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-07"},{"id":"e32ff061-efec-4127-94d5-8342bcf464d8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05242822","created_at":"2022-02-16T15:53:29.200Z","updated_at":"2024-07-02T16:35:06.798Z","phase":"Phase 1","brief_title":"A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations","source_id_and_acronym":"NCT05242822","lead_sponsor":"Kinnate Biopharma","biomarkers":" FGFR2","pipe":"","alterations":" ","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIN-3248"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 04/18/2022","start_date":" 04/18/2022","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-04-30"},{"id":"5cbd364b-f758-45a6-86eb-66a9228fce4b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06302621","created_at":"2024-03-13T01:30:21.478Z","updated_at":"2024-07-02T16:35:07.278Z","phase":"Phase 1","brief_title":"Pemigatinib + Afatinib in Advanced Refractory Solid Tumors","source_id_and_acronym":"NCT06302621","lead_sponsor":"Massachusetts General Hospital","biomarkers":" FGFR2","pipe":"","alterations":" ","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib) • Pemazyre (pemigatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 07/01/2024","start_date":" 07/01/2024","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-26"},{"id":"e391f2a5-896d-4821-b066-fdd97cba862d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04919642","created_at":"2021-06-10T01:52:34.634Z","updated_at":"2024-07-02T16:35:07.347Z","phase":"Phase 2","brief_title":"Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma","source_id_and_acronym":"NCT04919642","lead_sponsor":"TransThera Sciences (Nanjing), Inc.","biomarkers":" FGFR2 • FGFR","pipe":" | ","alterations":" FGFR2 mutation • FGFR2 fusion • FGFR mutation • FGFR1 mutation • FGFR1 fusion • FGFR wild-type","tags":["FGFR2 • FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation • FGFR2 fusion • FGFR mutation • FGFR1 mutation • FGFR1 fusion • FGFR wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tinengotinib (TT-00420)"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 12/07/2021","start_date":" 12/07/2021","primary_txt":" Primary completion: 02/28/2024","primary_completion_date":" 02/28/2024","study_txt":" Completion: 02/28/2024","study_completion_date":" 02/28/2024","last_update_posted":"2024-04-26"},{"id":"87f0861a-71c2-4555-9071-1764face39ce","acronym":"","url":"https://clinicaltrials.gov/study/NCT04641871","created_at":"2021-08-24T14:53:56.048Z","updated_at":"2024-07-02T16:35:07.851Z","phase":"Phase 1","brief_title":"Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies","source_id_and_acronym":"NCT04641871","lead_sponsor":"Symphogen A/S","biomarkers":" FGFR2 • IDH1","pipe":" | ","alterations":" IDH1 mutation • FGFR2 mutation • FGFR2 fusion","tags":["FGFR2 • IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • FGFR2 mutation • FGFR2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • S95018 • Sym021 • Sym022"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 10/12/2020","start_date":" 10/12/2020","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-04-24"},{"id":"b2993259-256a-4604-9f68-777de564f0ad","acronym":"FOENIX-CCA2","url":"https://clinicaltrials.gov/study/NCT02052778","created_at":"2021-01-17T17:33:24.806Z","updated_at":"2024-07-02T16:35:13.841Z","phase":"Phase 1/2","brief_title":"A Study of TAS-120 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT02052778 - FOENIX-CCA2","lead_sponsor":"Taiho Oncology, Inc.","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 fusion • FGFR3 mutation • FGFR fusion • FGFR2 rearrangement • FGFR3 fusion","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 fusion • FGFR3 mutation • FGFR fusion • FGFR2 rearrangement • FGFR3 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lytgobi (futibatinib)"],"overall_status":"Completed","enrollment":" Enrollment 407","initiation":"Initiation: 07/21/2014","start_date":" 07/21/2014","primary_txt":" Primary completion: 10/01/2020","primary_completion_date":" 10/01/2020","study_txt":" Completion: 05/29/2021","study_completion_date":" 05/29/2021","last_update_posted":"2024-03-20"},{"id":"bd0915a0-fd20-4277-b54e-97bf1a6410c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03452774","created_at":"2021-01-18T17:01:36.578Z","updated_at":"2024-07-02T16:35:14.464Z","phase":"","brief_title":"SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry","source_id_and_acronym":"NCT03452774","lead_sponsor":"Massive Bio, Inc.","biomarkers":" EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703","pipe":" | ","alterations":" HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation","tags":["EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 50000","initiation":"Initiation: 01/01/2018","start_date":" 01/01/2018","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-03-15"},{"id":"94fc3ab5-0532-4f36-b807-3064b8e380bd","acronym":"FIGHT","url":"https://clinicaltrials.gov/study/NCT03694522","created_at":"2021-01-17T17:12:46.809Z","updated_at":"2024-07-02T16:35:17.364Z","phase":"Phase 2","brief_title":"A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer","source_id_and_acronym":"NCT03694522 - FIGHT","lead_sponsor":"Five Prime Therapeutics, Inc.","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 amplification • FGFR2 overexpression • FGFR2b overexpression","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 amplification • FGFR2 overexpression • FGFR2b overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • leucovorin calcium • bemarituzumab (AMG 552)"],"overall_status":"Completed","enrollment":" Enrollment 155","initiation":"Initiation: 09/14/2018","start_date":" 09/14/2018","primary_txt":" Primary completion: 09/23/2020","primary_completion_date":" 09/23/2020","study_txt":" Completion: 05/13/2022","study_completion_date":" 05/13/2022","last_update_posted":"2024-02-28"},{"id":"7081cc15-ba4e-458b-8ca4-38802c059b4f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04507503","created_at":"2021-01-19T20:11:47.503Z","updated_at":"2024-07-02T16:35:17.897Z","phase":"","brief_title":"Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements","source_id_and_acronym":"NCT04507503","lead_sponsor":"Taiho Oncology, Inc.","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 rearrangement","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lytgobi (futibatinib)"],"overall_status":"Approved for marketing","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2024-02-23"}]